{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:51Z","timestamp":1786119171591,"version":"build-2736575974"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,19]]},"DOI":"10.1097\/qad.0b013e32832b4271","type":"journal-article","created":{"date-parts":[[2009,6,9]],"date-time":"2009-06-09T03:18:34Z","timestamp":1244517514000},"page":"1245-1254","source":"Crossref","is-referenced-by-count":21,"title":["The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies"],"prefix":"10.1097","volume":"23","author":[{"given":"I Mary","family":"Poynten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona Y","family":"Millwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O","family":"Falster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lut","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1126\/science.1160355","article-title":"Whither or wither microbicides?","volume":"321","author":"Grant","year":"2008","journal-title":"Science"},{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/00002030-199908200-00011","article-title":"Phase 1 trial of nonoxynol-9 film among sex workers in South Africa","volume":"13","author":"Rustomjee","year":"1999","journal-title":"AIDS"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00002030-199804000-00013","article-title":"Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection","volume":"12","author":"Van Damme","year":"1998","journal-title":"AIDS"},{"key":"R4-7-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007435-199705000-00008","article-title":"Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes: a randomised clinical trial","volume":"24","author":"Martin","year":"1997","journal-title":"Sex Transm Dis"},{"key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00002030-200001070-00010","article-title":"Safety of multiple daily applications of COL-1492 a nonoxynol-9 vaginal gel, among female sex workers","volume":"14","author":"Van Damme","year":"2000","journal-title":"AIDS"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(00)00138-4","article-title":"A new vaginal antimicrobial contraceptive formulation: phase 1 clinical pilot studies","volume":"62","author":"Lapido","year":"2000","journal-title":"Contraception"},{"key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0020-7292(99)00175-7","article-title":"Safety of three formulations of nonoxynol-9 containing vaginal spermicides","volume":"68","author":"Coggins","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"R8-7-20210130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095646249300400308","article-title":"A dosing study of nonoxynol-9 and genital irritation","volume":"4","author":"Roddy","year":"1993","journal-title":"Int J STD AIDS"},{"key":"R9-7-20210130","first-page":"327","article-title":"Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects","volume":"17","author":"Stafford","year":"1998","journal-title":"JAIDS"},{"key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00002030-200411050-00012","article-title":"Nonoxynol-9 100 mg gel: multisite safety study from sub-Saharan Africa","volume":"18","author":"Hoffman","year":"2004","journal-title":"AIDS"},{"key":"R11-7-20210130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJM199808203390803","article-title":"A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases","volume":"339","author":"Roddy","year":"1998","journal-title":"N Engl J Med"},{"key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.287.9.1117","article-title":"Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial","volume":"287","author":"Roddy","year":"2002","journal-title":"JAMA"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(02)11079-8","article-title":"Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial","volume":"360","author":"Van Damme","year":"2002","journal-title":"Lancet"},{"key":"R17-7-20210130","first-page":"1","article-title":"In vitro and in vivo: the story of nonoxynol-9","volume":"39","author":"Hillier","year":"2005","journal-title":"JAIDS"},{"key":"R19-7-20210130","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1371\/journal.pone.0001474","article-title":"SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria","volume":"3","author":"Feldblum","year":"2008","journal-title":"PLoS ONE"},{"key":"R20-7-20210130","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1371\/journal.pone.0001312","article-title":"SAVVY(R) (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana","volume":"2","author":"Peterson","year":"2007","journal-title":"PLoS ONE"},{"key":"R22-7-20210130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa0707957","article-title":"Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission","volume":"359","author":"Van Damme","year":"2008","journal-title":"N Engl J Med"},{"key":"R24-7-20210130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(07)60202-5","article-title":"Microbicide drug candidates to prevent HIV infection","volume":"369","author":"Balzarini","year":"2007","journal-title":"Lancet"},{"key":"R25-7-20210130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.biologicals.2006.08.002","article-title":"Microbicides: a new frontier in HIV prevention","volume":"34","author":"McGowan","year":"2006","journal-title":"Biologicals"},{"key":"R26-7-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1381612043386374","article-title":"Clinical development of microbicides for the prevention of HIV infection","volume":"10","author":"D'Cruz","year":"2004","journal-title":"Current Pharm Design"},{"key":"R29-7-20210130","first-page":"285","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","author":"Deeks","year":"2001"},{"key":"R30-7-20210130","first-page":"327","article-title":"Safety and acceptability of the candidate microbicide Carraguard in Thai women","volume":"43","author":"Kilmarx","year":"2006","journal-title":"JAIDS"},{"key":"R31-7-20210130","first-page":"538","article-title":"Carraguard vaginal gel safety in HIV-positive women and men in South Africa","volume":"46","author":"van de Wijgert","year":"2007","journal-title":"JAIDS"},{"key":"R32-7-20210130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/OLQ.0b013e31815d6e0d","article-title":"A randomized, placebo-controlled trial to assess the safety and acceptability of use of Carraguard vaginal gel by heterosexual couples in Thailand","volume":"35","author":"Kilmarx","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R33-7-20210130","first-page":"253","article-title":"No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial","volume":"47","author":"Bollen","year":"2008","journal-title":"JAIDS"},{"key":"R34-7-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0010-7824(01)00271-2","article-title":"Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety an colposcopy study","volume":"64","author":"Mauck","year":"2001","journal-title":"Contraception"},{"key":"R35-7-20210130","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.aids.0000194797.59046.8f","article-title":"Expanded phase I safety and acceptability study of 6% cellulose sulphate vaginal gel","volume":"19","author":"Malonza","year":"2005","journal-title":"AIDS"},{"key":"R36-7-20210130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/01.aids.0000226950.72223.5f","article-title":"Safety and acceptability of cellulose sulphate as a vaginal microbicide in HIV-infected women","volume":"20","author":"El-Sadr","year":"2006","journal-title":"AIDS"},{"key":"R37-7-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.contraception.2006.02.008","article-title":"Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomised double-blind phase I safety study","volume":"74","author":"Schwartz","year":"2006","journal-title":"Contraception"},{"key":"R38-7-20210130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.contraception.2007.05.083","article-title":"Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days","volume":"76","author":"Doh","year":"2007","journal-title":"Contraception"},{"key":"R39-7-20210130","first-page":"213","article-title":"A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide","volume":"14","author":"Stafford","year":"1997","journal-title":"JAIDS"},{"key":"R40-7-20210130","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1086\/517820","article-title":"Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1","volume":"177","author":"Rosenstein","year":"1998","journal-title":"J Infect Dis"},{"key":"R41-7-20210130","first-page":"391","article-title":"Dextrin sulphate as a vaginal microbicide: randomised double-blind, placebo-controlled trial including healthy female volunteers and their male partners","volume":"31","author":"Low-Beer","year":"2002","journal-title":"JAIDS"},{"key":"R42-7-20210130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.olq.0000175380.27057.2c","article-title":"A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers","volume":"32","author":"McCormack","year":"2005","journal-title":"Sex Transm Dis"},{"key":"R43-7-20210130","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/01.aids.0000194129.05264.55","article-title":"A randomised controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda","volume":"19","author":"Bakobaki","year":"2005","journal-title":"AIDS"},{"key":"R44-7-20210130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/jwh.2006.0224","article-title":"Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally","volume":"16","author":"Hemmerling","year":"2007","journal-title":"J Women's Health"},{"key":"R45-7-20210130","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/infdis\/171.6.1611","article-title":"Frequent use of Menfegol spermicidal vaginal foaming tablets associated with a high incidence of vaginal lesions","volume":"171","author":"Goeman","year":"1995","journal-title":"J Infect Dis"},{"key":"R46-7-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.contraception.2004.02.016","article-title":"Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study","volume":"70","author":"Mauck","year":"2004","journal-title":"Contraception"},{"key":"R47-7-20210130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/sti.76.2.126","article-title":"A phase I study of a novel potential intravaginal microbicide, PRO2000, in healthy sexually inactive women","volume":"76","author":"Van Damme","year":"2000","journal-title":"Sex Transm Inf"},{"key":"R48-7-20210130","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/01.aids.0000222075.83490.ca","article-title":"Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study","volume":"20","author":"Lacey","year":"2006","journal-title":"AIDS"},{"key":"R49-7-20210130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QAD.0b013e328013d9b5","article-title":"PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity","volume":"21","author":"Keller","year":"2007","journal-title":"AIDS"},{"key":"R50-7-20210130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0010-7824(02)00433-X","article-title":"Safety of single daily use for one week of C31G HEC gel in women","volume":"66","author":"Ballagh","year":"2002","journal-title":"Contraception"},{"key":"R51-7-20210130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/OLQ.0b013e31816766af","article-title":"Phase I clinical trial of repeat dose Terameprocol vaginal ointment in healthy female volunteers","volume":"35","author":"Khanna","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R52-7-20210130","first-page":"154","article-title":"Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers","volume":"44","author":"Jespers","year":"2007","journal-title":"JAIDS"},{"key":"R53-7-20210130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/OLQ.0b013e318162c4d8","article-title":"A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a nonnucleoside reverse transcriptase inhibitor","volume":"35","author":"Schwartz","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R54-7-20210130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.contraception.2007.10.006","article-title":"Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials","volume":"77","author":"van de Wijgert","year":"2008","journal-title":"Contraception"},{"key":"R55-7-20210130","first-page":"203","article-title":"Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women","volume":"48","author":"van de Wijgert","year":"2008","journal-title":"JAIDS"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e32832b4271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:54:42Z","timestamp":1786038882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200906190-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,19]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832b4271","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6,19]]}}}